...
XOMASMALL

XOMA Royalty Corp.

HealthcareBiotechnology
$25.54
$0.00(+0.04%)
52W$18.35
$39.92
FinancialsValuationvs RPRX
Updated Mar 4, 12:00 AM
RSI49
RS Rating33/99
Beta0.82
Volatility56%
F-Score4/9
Mkt Cap$305M
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

XOMA Royalty Corp. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 33), showing significant lag compared to the market leaders. Earnings growth of 144% provides fundamental context to the price action. Investors should exercise caution due to high volatility (56% annualized), which requires wider risk management.

Relative Strength
33
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
0.82
vs S&P 500
DEFENSIVE
52W Position
33%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$26.03
50 SMA > 100 SMA$29.36
100 SMA > 150 SMA$30.76
150 SMA > 200 SMA$29.53

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$25.16+1.50%ABOVE
50 SMA$26.03-1.89%BELOW
100 SMA$29.36-13.01%BELOW
150 SMA$30.76-16.97%BELOW
200 SMA$29.53-13.50%BELOW

Price Performance

1D+0.0%
1W-4.5%
1M-5.1%
3M-18.0%
6M-27.9%
YTD-8.8%
1Y+21.7%
3Y+6.2%
52-Week Trading Range33% from low
$25.54
52W Low$18.35
52W High$39.92

Technical Indicators

RSI (14)NEUTRAL
49.2
305070
VCP ScoreCOOL
5/10
Base depth: 48.9%

Risk Profile

Beta
0.82
52W Vol
56%
ATR
$1.27
Max DD (1Y)
-42%

Volume Analysis

Today
25
50D Avg
477.8K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+76%
$-0.45
Q1'25+108%
$0.07
Q2'25-65%
$0.44
Q3'25+144%
$0.70
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+4.21%
5 Years:+9.17%
3 Years:-9.28%
TTM:+191.25%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+124.68%

Stock Price CAGR

10 Years:+4.53%
5 Years:-6.29%
3 Years:+6.17%
1 Year:+21.68%

Return on Equity

10Y Avg:-568.1%
5Y Avg:-6.6%
3Y Avg:-22.5%
Last Year:17.9%

Key Metrics

Market Cap$305M
Gross Margin99.3%
Net Margin-48.5%
Piotroski F-Score4/9

More XOMA Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

XOMA vs RPRXRPRXLGNDINVABTX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 33 meansXOMA outperformed 33% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.82 means 18% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is XOMA in an uptrend right now?

XOMA has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is XOMA overbought or oversold?

XOMA's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.

Is XOMA outperforming the market?

XOMA has a Relative Strength (RS) Rating of 33 out of 99. XOMA is currently lagging the broader market.

Where is XOMA in its 52-week range?

XOMA is trading at $25.54, which is 64% of its 52-week high ($39.92) and 33% above its 52-week low ($18.35).

How volatile is XOMA?

XOMA has a Beta of 0.82 and 52-week volatility of 56%. It's less volatile than the S&P 500 - generally more stable.